Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
Main finding · MLOResult — go to the resultAdjusted hazard ratio 0.82 95% CI 0.60–1.10Authors' conclusion
In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to support the decision to switch from DPP4is.
Study context
- Population
- Adults with T2D and MASLD using metformin, without specific liver conditions or surgeries, Merative MarketScan database, initiating 1 January 2014 to 31 December 2022
- Participants
- 44,651 adults
- Exposure
- SGLT2i vs DPP-4i initiation
- SGLT2in = 22,100
- DPP4in = 22,551reference
- Outcome
- Time to major liver outcome (major liver outcomes (MLO)) diagnosis
Methodological detailsoverlap weighting, Cox proportional hazards model
- Overlap weighting
- Cox proportional hazards model
Main finding
MLO
Adjusted hazard ratio
0.82
95% CI 0.60–1.10
By group
SGLT2i
3.8 per 1000 person-years
DPP4i
3.9 per 1000 person-years
SGLT2ivs DPP4i
aHR 0.82 (95% CI 0.60–1.10)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| Cirrhosis | 0.77 (0.55–1.06) | |
| Hepatocellular carcinoma | 0.99 (0.47–1.83) | |
| 0.512Adjusted hazard ratio (log scale) |
Subgroup and sensitivity analyses
- Subgroup and sensitivity analyses did not yield significant results
Original publication
Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease. Diabetes Obes Metab. Published 12 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →